Conclusions: In LMCA stenosis without significant aorto-ostial stenosis, both strategies of with or without aorto-ostial coverage showed similar clinical outcomes at 2 years.

TCT-224
Trends in Revascularization Strategy and Outcomes in Left Main Stenosis: Data from ASAN MAIN Registry

Seung-Jung Park1, Jung-Min Ahn1, Se Hun Kang1, Hee-Soon Park1, Sang Soo Cheon1, Min Su Kim1, Jae Hyung Roh1, Young-Hak Kim1, Duk-Woo Park1, Sung-Han Yoon1, Hyun Woo Park1, Mineok Chang1, Jong-Young Lee1, Soo-Jin Kang1, Seung-Whan Lee1, Cheol Whan Lee1, Seong-Wook Park1

Background: Changes in revascularization strategies and outcomes among patients with significant unprotected left main coronary artery (LMCA) stenosis remain largely unknown.

Methods: A total of 2618 consecutive patients with LMCA stenosis undergoing revascularization treatment between 1995 and 2010 were identified from ASAN MAIN registry. Patients were classified into three periods: bare metal stent (WAVE1) period (1995-1998), early drug-eluting stent (WAVE2) period (2003-2006), and late drug-eluting stents (WAVE3) period (2007-2010). The major adverse cerebro-cardiovascular events (MACCE) were defined as death, myocardial infarction, repeat revascularization, or stroke at 2-years.

Results: The major adverse cerebro-cardiovascular events (MACCE) were defined as death, myocardial infarction, repeat revascularization, or stroke at 2-years.During study periods, 1124 patients underwent percutaneous coronary intervention (PCI) with stent and 1494 patients underwent coronary artery bypass grafting (CABG). The proportion of PCI significantly increased from 35% to 52%. Among patients receiving PCI, the risk-adjusted incidence rate of MACCE decreased from 20.18 cases per 100 person-years in WAVE1 to 6.77 cases per 100 person-years in WAVE3 (P< 0.001 for trend). Death, the composite of death, myocardial infarction, or stroke, and repeat revascularization were also significantly decreased by 40%, 35%, and 46%, respectively. However, among patients receiving CABG, the risk-adjusted incidence rate of MACCE was not significantly changed during study period. In addition, the difference in the risk of MACCE between PCI and CABG progressively reduced (adjusted hazard ratio [95% confidence interval]: 0.33 [0.23-0.47], 0.53 [0.35-0.80], and 1.01 [0.08-1.09] from WAVE1 through WAVE3.

Conclusions: The outcomes of PCI for LMCA stenosis have significantly improved and PCI has successfully substituted CABG in a significant proportion of patients with LMCA stenosis.

TCT-225
Dedicated Bifurcation BioOSS® Stent In The Treatment Of Distal Left Main Stem Stenosis – International Registry

Jacek Bil1, Robert J. Gill2, Dobrin Vassilev3, Luis A. Figueroa-García4, Leticia Fernandez-Lopez1, Tomasz Pawlowski1

1Central Clinical Hospital of the Ministry of the Interior, Warsaw, Poland, 2Institute of Experimental and Clinical Medicine, Polish Academy of Science, Warsaw, Poland, 3National Heart Hospital, Sofia, Bulgaria, 4Hospital Costa del Sol, Marbella, Malaga, 5Hospital Costa del Sol, Marbella, Malaga

Background: The aim of this study was to assess efficacy and safety profile of distal LM stenosis treatment with dedicated bifurcation BioOSS stents (Balton, Poland): in

group I - paclitaxel-eluting BioOSS Expert® and in group II - sirolimus-eluting BioOSS LIM®.

Methods: Patients with CAD or NSTE-ACS were enrolled between January 2011 and June 2013 in three centers in Bulgaria, Poland and Spain. Decision for LM stenting was based on Heart Team consensus. Provisional T-stenting was default strategy. Continued angiography was planned at 12 months in all patients. The primary end point is MACE at 12 months. Here, we present 6-month clinical data from both groups and completed angiographic data from BioOSS Expert. At the time of TCT 2014 angiographic data from BioOSS LIM will be completed.

Results: There were enrolled 158 patients (64% BioOSS Expert group and 36% in BioOSS LIM group). The average age was 65.7±12.5 yrs and 19.7% were female. In the study 17.8% of patients were with NSTE-ACS, 73.4% with hypertension, 81.4% with dyslipidemia, 32.1% with diabetes, 39.2% with prior MI, 43.3% with prior PCI and 17.4% with prior CABG. The mean SYNTAX score was 21.52±6.58. True bifurcations were treated in 70.1% of cases. All BioOSS® stents were implanted successfully. The nominal stent parameters were as followed: BioOSS Expert group: 4.07±0.26mm (proximal diameter) x 3.36±0.26mm (distal diameter) x 16.61±1.72 mm (length) and BioOSS LIM group: 3.90±0.40mm x 3.17±0.39mm x 16.8±2.06mm. Classical DES in side branch was implanted in 29.9% and 21.4%, respectively. Almost 62% of procedures were done from radial access and 83% with 6F catheter. After 12 months in BioOSS Expert group angiographically-driven TLR rate was 9.6%, whereas clinically-driven TLR was 3.2%. In BioOSS LIM group data are pending - at 6 months there were no death or MI. In BioOSS Expert group late lumen loss was as follows: in main vessel - 0.21±0.1mm, in main branch – 0.26±0.12mm and in side branch – 0.14±0.09mm.

Conclusions: Dedicated bifurcation BioOSS stents seem feasible devices with promising effectiveness and safety profile in distal LM stenosis. Complete BioOSS LIM data facilitate to answer the question if the used drug or stent design is more crucial.

TCT-226
Impact of Final Kissing Balloon Inflation Following Single-stent Strategy in Unprotected Left Main Lesion

Yasuke Watanabe1, Kenzuke Takagi2, Sunao Nakamura3

1New Tokyo Hospital, Matsudo, Chiba, Japan, 2New-Tokyo Hospital, Japan, 3New Tokyo Hospital, Matsudo, Chiba

Background: Final kissing balloon inflation (FKBI) is a mandatory technique in unprotected left main (ULM) revascularization with 2-stent strategy. However, there is no consensus regarding the necessity of FKBI in single-stent strategy. Therefore, to assess the need of FKBI for single-stent strategy in ULM lesion, we compared clinical outcome between patients treated using single-stent strategy with FKBI and those without FKBI.

Methods: A total of 654 consecutive patients who had ULM lesion were treated using drug-eluting stent between April 2005 and August 2010. Of these, 470 patients were eligible in this study after exclusion of 21 patients with ostial ULM and 163 patients treated using 2-stent strategy. In patients using single-stent strategy, 357 patients were proceeded with FKBI (FKBI group) and 113 patients were without FKBI (no-FKBI group). The end point of this study is the occurrence of Major Adverse Cardiovascular Event (MACE) defined as composites of all cause death, target lesion revascularization (TLR) and MI. Furthermore, overall TLR, TLR for main branch (TLR-MB) involving ULM to left anterior descending artery and TLR for side branch alone (TLR-SB) involving left circumflex (LCx) at 1-year were evaluated.

Results: Patient and lesion characteristics were similar between the 2 groups. Following single-stent strategy, 36 patients (8.9%) necessitated an additional bailout stenting for ostial LCx stenosis. In the total population, the occurrence of MACE at 1 year is similar between the two groups (7.4% in the FKBI group and 11.9% in the no-FKBI group, log rank p=0.112). The incidences of overall TLR, TLR-MB and TLR-SB at 1 year were also similar between FKBI group vs. no-FKBI group (7.0% vs. 9.3%, 4.5% vs. 4.4%, 2.5% vs. 4.7%, p=0.24 and 5.0% vs.5.6%, p=0.34, retrospectively).

Conclusions: Single-stent for ULM disease was feasible at mid-term follow-up. However, FKBI had no impact on clinical outcome following ULM revascularization with Single-stent strategy.

TCT-227
Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting For Unprotected Left Main Stenosis with Severe Left Ventricular Dysfunction: Data from ASAN MAIN Registry

Min Su Kim1, Jung-Min Ahn1, Hee-Soon Park1, Se Hun Kang1, Sang Soo Cheon1, Byeong Joo Bae1, Jae Hyung Roh1, Hyun Woo Park1, Mineok Chang1, Sung-Han Yoon1, Jong-Young Lee1, Duk-Woo Park1, Soo-Jin Kang1, Seung-Whan Lee1, Young-Hak Kim1, Cheol Whan Lee1, Seong-Wook Park1, Seung-Jung Park1

1Asan Medical Center, Seoul, Korea, Republic of

Background: Unprotected left main coronary artery (ULMCA) stenting has been investigated as an alternative to coronary artery bypass grafting (CABG). However, long-term benefits of PCI or CABG in patients with ULMCA disease and severe left ventricular dysfunction (LVD) have not been established.

Methods: Between March 1992 to February 2011, a total of 213 patients with significant ULMCA disease and severe LVD (ejection fraction [EF] of 40% or less) who underwent PCI (42 patients) or CABG (171 patients) were identified from ASAN MAIN Registry. Primary endpoint was all-cause death at 2 years.
TCT-228

Long-term Safety and Efficacy of Sirolimus Eluting Stent Implantation for Unprotected Left Main Trunk Bifurcation Lesion with Single Stent Strategy

Takahiro Toba1, Shinichiro Yamada1, Yoshinori Yasaka2, Shogo Oishi3, Akira Shimane1, Hiroya Kawai4

1Himeji Cardiovascular Center, Himeji, Hyogo, 2Himeji cardiovascular Center, Himeji, Hyogo

Methods: We assessed occurrence of MACE (a composite of cardiac death, non-fatal myocardial infarction (MI), and target lesion revascularization (TLR)) and other endpoints in 31,469 patients with unprotected left main trunk bifurcation lesion treated with single stent strategy. The current study demonstrates that novel LMCA stenting technique with single stent strategy is feasible and safe for ostial/midshaft lesions.

Conclusions: DES implantation with single stent strategy for ULMT bifurcation lesion provides as feasible long-term outcome as for LAD lesion.

TCT-229

First generation versus new generation drug-eluting stents for the treatment of ostial/midshaft lesions in unprotected left main coronary artery: The Milan and New-Toyko (MITO) registry

Tora Nagamura1, Alade Chienni2, Kento Okuyama1, Tatsuya Oonuki1, Takeshi Kadowaki1, Takeshi Tanaka1, Shingo Okuda1, Yoshihiko Terada1, Kenji Togawa1, Tatsuya Moto1, Kenji Kato1, Shun Suzuki2, Kenji Nagai3, Toshihito Okabe4, Shigeo Hori5, Minoru Hirasawa5, Takanori Ishida1, Kiyotaka Kitaoka1, Shunji Onoda1, Hisao Yoshida1, Tatsuya Naito1, Takehito Suzuki1, Takahiro Sato1, Shinya Sakurai1, Kenji Kato1, Hidetoshi Hara1, Hideki Nishikawa1, Hiroyasu Uesugi1, Naoya Sakagami1, Kenji Ohkura1, Kenji Itoh1, Hiroshi Hayashi1, Koji Yoneda1, Kenji Nagata1, Junji Saisho1, Masahiro Kato1, Masahito Uchida1, Masahiro Takeuchi1, Kiyoshi Kato1, Takayoshi Toba1, Shinichiro Yamada1, Yoshinori Yasaka2, Shogo Oishi3, Akira Shimane1, Hiroya Kawai4

1San Raffaele Scientific Institute, Milan, Italy, 2San Raffaele Scientific Institute, Milan, Italy, Milan, Italy, 3New-Toyko Hospital, Japan, Matsudo, Japan, 4Imperial College London, London, Greater London, 5New Tokyo Hospital, Chiba, Japan, 6Hammersmith Hospital, London, London, 7New Tokyo Hospital, Matsudo, Japan, 8San Raffaele Scientific Institute, Milano, Milano, 9Ospedale San Raffaele, Milano, Italy, 10EMO GVM centro cuore Columbus / San Raffaele Scientific Institute, Milan, Lombardia, 11EMO GVM Centro Cuore Columbus/Ospedale San Raffaele, Milano, Italy, 12San Raffaele scientific institute, Milano, Milano, 13San Raffaele Hospital, Milano, Milan, Italy, 14EMO GVM Centro Cuore Columbus/San Raffaele Hospital, Milano, Italy

Background: Clinical outcomes after treatment of ostial/midshaft lesions in unprotected left main coronary artery (ULMCA) with first generation drug-eluting stents (DES) have been found to be favorable. However, to date, data regarding new generation DES for these lesion subsets have not been reported. The aim of this study was to compare the clinical outcomes following ULMCA percutaneous coronary intervention (PCI) of ostial/midshaft lesions with first versus new generation DES.

Methods: A total of 219 patients from the Milan New-Toyko (MITO) registry with ostial/midshaft lesions in ULMCA treated with first (n=139) or new generation DES (n=80) were analyzed.

Results: The first generation DES group had more males (78.4% vs. 63.8%; p=0.026). There was a higher prevalence of IVUS use (35.2% vs. 50.0%; p=0.032) and post-dilation (70.5% vs. 93.8%; p<0.001) with larger maximum balloon diameter (3.81±0.45 vs. 4.08±0.44, p<0.001) in the new generation DES group. At a median follow-up period of 730 days, there were no significant differences in the propensity-score adjusted analyses, for major adverse cardiac events (MACE) as composite endpoint of all-cause death, myocardial infarction and target vessel revascularization (HR [new vs. first generation DES]: 1.22; 95% CI: 0.64 to 2.31; p=0.549). Of note, target lesion revascularization rates at 2-years were only 0.9% and 2.7%, for first and new generation DES groups, respectively (p=0.339). On multivariable analysis, SYNTAX score (HR: 1.06; 95% CI: 1.02-1.11, p=0.006) and EuroSCORE (HR: 1.14; 95% CI: 1.00-1.31, p=0.051) were independent predictors for MACE.

Conclusions: This study suggests that new generation DES for ostial/midshaft lesions in ULMCA are associated with favorable clinical outcomes, comparable to those observed with first generation DES.

TCT-230

Distant LMCA Lesions Treated with DES and Absorb. The Novel Technique. 30 Day Follow-up

Andrejs Erglis1, Inga Narbule1, Sanda Jegere2, Dace Sondere3, Indulis Kumsars4, Ieva Briede1, Andis Dombrovskis2, Alona Grave3, Agnese Knips4, Ievu Mintale9

1Pauls Stradins Clinical University Hospital, Riga, Latvia, 2Pauls Stradins Clinical University Hospital, Riga, Latvia, 3Pauls Stradins Clinical University Hospital, Riga, Latvia, 4Latvian Cardiology Center, Riga, Latvia, 5Latvian Cardiology Center, Riga, Latvia, 6Latvian center of cardiology, Paul Stradins Clinical University Hospital, Riga, Latvia, 7Pauls Stradins Clinical University Hospital, Riga, Latvia

Background: Percutaneous coronary intervention (PCI) with drug eluting stent (DES) implantation for left main coronary artery (LMCA) stenosis has been shown to be a feasible and safe approach. However, optimal stenting technique is still under discussion. Our goal is to evaluate safety and efficacy of novel stenting technique in LM distal lesions - intravascular ultrasound (IVUS) guided and optical coherence tomography (OCT) optimized everolimus eluting platinum chromium stent (SYNERGY) and bioreabsorbable coronary scaffold (ABSORB) implantation.

Methods: 31 patient with distal LMCA are enrolled in ongoing study at Latvian Center of Cardiology. All interventions were IVUS guided and OCT optimized. Plaque modification with cutting balloon before stenting was performed. SYNERGY stent was implanted across the CX followed by ABSORB implantation at the proximal CX. Procedure is finished with “kissing” post-dilation. 12-month angiographic, IVUS and OCT follow-up is ongoing.

Results: All patients underwent the procedure due to stable angina, 25 (81%) of them were males. Mean patient age was 62±11 years, 26 (85%) of them were hypertonic with dyslipidemia, 7 (23%) suffered from diabetes mellitus and were smokers. Mean SYNTAX score 27.6±2.6, Synergy stent length implanted in LM-LAD was 23.6±5.3 mm, diameter 3.75±0.27 mm. Mean Absorb scaffold length implanted in LM-LCX was 16.3±1.0 mm, diameter 3.2±0.3 mm. Stenting technique: mean crush 21. There were no procedural complications. No major cardiac adverse events occurred during hospitalization period and 30 day follow-up.

Conclusions: The current study demonstrates that novel LMCA stenting technique using SYNERGY stent and ABSORB scaffold is safe and feasible. No serious